Synexus Polska Sp. z o.o.
- Address
- Ul. Luzycka 3c, 81-537 Gdynia, Poland
Synexus Polska Sp. z o.o. - Multi-Specialty Clinical Research Center
Synexus Polska Sp. z o.o. is a comprehensive clinical research facility conducting Phase 3 trials across diverse therapeutic areas. The center demonstrates particular expertise in metabolic disorders, pain management, neurological conditions, and vaccine development, supporting the advancement of innovative therapies from late-stage development through regulatory approval.
- Metabolic and hepatic disorders, including metabolic dysfunction-associated steatohepatitis (MASH) and fibrosis progression studies
- Neurological therapeutics, specializing in chronic and episodic migraine prevention with botulinum toxin formulations
- Pain management research, focusing on chronic peripheral neuropathic pain conditions including postherpetic neuralgia and nerve injury-related pain
- Musculoskeletal health and vaccine development, including post-menopausal osteoporosis biosimilar studies and extraintestinal pathogenic E. coli prevention
The center's research portfolio reflects significant involvement in comparative effectiveness trials and biosimilar development programs, particularly in bone health therapeutics. With expertise spanning from chronic disease management to preventive medicine, Synexus Polska conducts rigorous placebo-controlled and comparative studies that evaluate both safety and efficacy outcomes. The facility's capabilities in managing complex patient populations, including elderly participants requiring co-administered vaccines and patients with severe chronic conditions, demonstrate its comprehensive clinical trial management expertise.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Top 5 of 6 therapeutic areas and 15 of 28 IMPs, ranked by number of trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 3 by active trials.
- 1Akero Therapeutics Inc.1active
lock +2 more on a paid plan
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
- 1Ipsen Innovation2trials
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 1 624 other sites in Poland
Therapeutic Area Benchmark — Poland
Select a therapeutic area to compare against other sites in Poland.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: Poland
Market Share
Country: Poland
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in Synexus Polska Sp. z o.o.
lock Showing 1 of 10 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| A parallel-group treatment, proof-of-concept Phase 2, multicenter, double-blind, randomized 2 arm clinical trial to investigate the efficacy and safety of subcutaneous NT 201 injections compared with placebo injections in decreasing pain intensity in male and female participants aged 18 years and older with moderate or severe chronic neuropathic pain due to postherpetic neuralgia or peripheral nerve injury. | Merz Therapeutics GmbH | Phase II | Not Recruiting | Oct 2023 | Jun 2025 |
IMP list
lock Showing 1 of 28 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Botulinum Toxin Type A - Haemagglutinin Complex | 2 | Unknown | 2024-03-18 | 2024-03-18 |
Request feasibility information
Ask this centre about capacity, equipment and patient population.
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.